onfekafusp alfa + pembrolizumab

A combination therapy consisting of **onfekafusp alfa** (also known as L19IL2) and **pembrolizumab**. Onfekafusp alfa is a fusion protein comprising the L19 antibody targeting the extra-domain B of fibronectin—which is highly expressed in the extracellular matrix of tumors—linked to interleukin-2 (IL-2), a cytokine that stimulates proliferation and activation of T cells and NK cells in the tumor microenvironment. **Pembrolizumab** is a monoclonal antibody that inhibits the programmed cell death 1 (**PD-1**) receptor on T cells, blocking the PD-1/PD-L1 interaction and releasing the immune response against cancer. The combination is explored for enhanced anti-tumor immune activation via complementary mechanisms: onfekafusp alfa recruits and activates immune cells within the tumor, and pembrolizumab inhibits tumor immune evasion. The combination is under investigation for advanced solid tumors, with clinical research in cancers such as melanoma and other indications[8].

Other names

L19IL2 + pembrolizumab